Abstract:Alport syndrome is a hereditary glomerular disease caused by mutation in the COL4A3, COL4A4, or COL4A5 gene encoding type IV collagen alpha 3, alpha 4, and alpha 5 chains (alpha 3-alpha 5(IV)), respectively, which are components of the glomerular basement membrane (GBM). The most common mutations are those in COL4A5, which comprise more than 80% of AS-associated mutations. Mutant achains cannot form alpha 345(IV) trimer, which leads to abnormal GBM. In current therapeutic approaches for the management of Alport syndrome, inhibitors of the renin angiotensin system (RAS) are typically prescribed. Although early intervention by RAS blockade suppresses the progression of nephritis, patients with Alport syndrome taking RAS inhibitor eventually develop end-stage renal disease. Numerous basic studies have revealed the molecules that are associated with the progression of Alport syndrome. However, candidate drug targets have not been assessed in clinical applications, and a novel therapeutic strategy is urgently needed. We have established collagen alpha 345(IV) heterotrimer formation assay system that is amenable to high throughput screening (HTS) by using split luciferase compliment system (NanoLucTM) (Omachi, et al., Cell Chem. Biol. 2018). The assay provided evidence that compared with wild-type alpha 345(IV) trimer, the heterotrimer with mutant alpha 5(IV) had either intracellular trimerization defect or trimer secretion defect. We have started screening of natural compounds in our original library using alpha 5(IV) G1244D-expressing cellular system, and are trying to find potential candidate compounds to correct the mutant alpha 5(IV)-dependent defect of alpha 345 (IV) trimer secretion. Furthermore, we will also discuss the recent progress on the generation of new Alport mouse models with missense mutations in C57BL/6 and 129 strains that may be usable for future analysis of the in vivo efficacy of our candidate compounds.

Alport syndrome and Alport kidney diseases – elucidating the disease spectrum

Alport Syndrome: a Unified Classification of Genetic Disorders of Collagen IV Alpha 345: a Position Paper of the Alport Syndrome Classification Working Group

Collagen IVα345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture’s and Alport diseases

Collagen IVα345 Dysfunction in Glomerular Basement Membrane Diseases. I. Discovery of a COL4A3 Variant in Familial Goodpasture's and Alport Diseases.

Pathological diagnosis of Alport syndrome

A Clinicopathological Study of Alport Syndrome and Detection of Type IV Collagen Chains in Alport Patients.

Genotype-Phenotype Correlations for Pathogenic COL4A3–COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome

Quantitative Analysis of Type IV Collagen Subchains in the Glomerular Basement Membrane of Patients with Alport Syndrome with Confocal Microscopy.

Pharmacological approach and diagnosis for Alport syndrome

Three Novel Heterozygous Col4a4 Mutations Result In Three Different Collagen Type Iv Kidney Disease Phenotypes

Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report

Adverse effects of Alport syndrome-related Gly missense mutations on collagen type IV: Insights from molecular simulations and experiments

Four novel mutations identified in the COL4A3, COL4A4 and COL4A5 genes in 10 families with Alport syndrome

Alport Syndrome —— an Analysis of 22 Families

Quantitative assessment of glomerular basement membrane collagen IV α chains in paraffin sections from patients with focal segmental glomerulosclerosis and Alport gene variants.

Alport syndrome: Expanding diagnosis and treatment

[Analysis of Alport Syndrome Induced by Type IV Collagen Alpha 5 Gene Mutation in Two Families].

Endoplasmic Reticulum Stress Activation in Alport Syndrome Varies Between Genotype and Cell Type

Spectrum of Clinical Features and Type IV Collagen Alpha-Chain Distribution in Chinese Patients with Alport Syndrome.

Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience

Siblings with Alport’s syndrome showing unique staining patterns for α5(IV) and α6(IV) chains of collagen type IV